Stereotaxis has announced that it has completed its previously announced acquisition of Robocath—an innovator of robotic technologies for interventional cardiology and neurointerventions.
As per a press release, Robocath will now be fully integrated into Stereotaxis, combining complementary technologies and expertise to accelerate the development of next-generation robotic solutions for electrophysiology, interventional cardiology, and neurointerventions.
This combined platform strengthens Stereotaxis’s position as a leader in robotic technologies across the full spectrum of endovascular procedures, according to the company.
“We’re very excited to join Stereotaxis,” said Robocath founder and chief executive officer (CEO) Philippe Bencteux. “Combining the strengths, expertise and technologies of two pioneers in endovascular robotics, we now have the opportunity to accelerate innovation, expand our global reach, and bring robotic solutions to many more physicians and patients around the world.”
“The addition of Robocath’s technology and team to Stereotaxis accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies in an expanded addressable market, and supports new strategic opportunities,” added Stereotaxis chairman and CEO David Fischel.
